8AW0 Stock Overview
A biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ocean Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.67 |
| 52 Week High | US$7.05 |
| 52 Week Low | US$0.48 |
| Beta | 1.53 |
| 11 Month Change | -23.86% |
| 3 Month Change | -26.37% |
| 1 Year Change | -31.35% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8AW0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.5% | -0.7% | 0.2% |
| 1Y | -31.4% | -17.2% | 8.5% |
Return vs Industry: 8AW0 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 8AW0 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 8AW0 volatility | |
|---|---|
| 8AW0 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 8AW0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8AW0's weekly volatility has decreased from 44% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | M. Berrey | www.oceanbiomedical.com |
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP.
Ocean Biomedical, Inc. Fundamentals Summary
| 8AW0 fundamental statistics | |
|---|---|
| Market cap | €23.96m |
| Earnings (TTM) | -€94.68m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs 8AW0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8AW0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$98.59m |
| Earnings | -US$98.59m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.85 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -22.8% |
How did 8AW0 perform over the long term?
See historical performance and comparison